Grants Still Most Expensive in the United States


Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-03-01-2012
Volume 21
Issue 3


Many factors affect a sponsor's decision to pick a region in which to conduct a clinical trial. Clinical grant expenditures represent a significant portion of later phase clinical trial budgets. Therefore, the relative cost per patient can play a large role in which region to select.

The cost per patient in Asia and Latin American is increasing much faster than in the United States.

TTC maintains annual current global data on the relative costs of clinical grants around the world in the GrantPlan® database. The database contains the clinical grants for sponsor companies and CROs that together conduct over 76% of all commercial clinical trials.

The current update demonstrates that, after controlling for study design, the United States remains the most expensive region for clinical grants by a large margin. Latin America and Asia exhibit less expensive costs per patient with 55% and 44% of the United States' 2009 cost per patient, respectively.

The cost per patient in these newer geographies, however, is growing more rapidly than in more established regions. The United States has been averaging 5.5% annual increases from 2009 through 2011, while grant costs in Asia and Latin America are growing at two to three times those rates.

—TTC - for more information, please contact

Recent Videos
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
© 2024 MJH Life Sciences

All rights reserved.